A Study of Pembrolizumab + Olaparib vs Abiraterone or Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (MK7339-010)
A Study of Pembrolizumab + Olaparib vs Abiraterone or Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (MK7339-010)
Trial Category:
Genitourinary
Phase
III
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
